Moreover, a multivariable analysis revealed that the low level of RECQL protein expression was an independent unfavorable factor for DRFS (adjusted HR: 2.12, 95% CI, 1.16–3.88; P = 0.015) in these 322 patients after adjustment for age of diagnosis, lymph node status, PR status, ER status, HER2 status, tumor size and adjuvant therapy (Table 4). The gene discussed is ERBB2; the disease is neoplasm.